From the Service de Médecine Interne, Centre Hospitalier Universitaire (CHU) de Nice, Nice; University of Lille, U995 Lille Inflammation Research International Center (LIRIC), Lille; INSERM, U995, Lille; CHU Lille, Département de Médecine Interne et Immunologie Clinique, Lille; Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), Lille; Service d'Explorations Fonctionnelles Respiratoires, CHU de Lille, Lille; FHU OncoAge, Côte d'Azur University, Nice, France.
N. Martis, MD, MS, Service de Médecine Interne, CHU de Nice; V. Queyrel-Moranne, MD, MS, Service de Médecine Interne, CHU de Nice; D. Launay, MD, PhD, Professor of Medicine, Univ. Lille, U995, LIRIC, INSERM U995, CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique); R. Neviere, MD, PhD, Professor of Medicine, Service d'Explorations Fonctionnelles Respiratoires, CHU de Lille; J.G. Fuzibet, MD, MS, Professor of Medicine, Service de Médecine Interne, CHU de Nice; C.H. Marquette, MD, PhD, Professor of Medicine, FHU OncoAge, Côte d'Azur University; S. Leroy, MD, FHU OncoAge, Côte d'Azur University.
J Rheumatol. 2018 Jan;45(1):95-102. doi: 10.3899/jrheum.161349. Epub 2017 Nov 1.
Exercise limitation in patients with systemic sclerosis (SSc) is often multifactorial and related to complications such as interstitial lung disease (ILD), pulmonary vasculopathy (PV), left ventricular dysfunction (LVD), and/or peripheral/muscular limitation (PML). We hypothesized that cardiopulmonary exercise testing (CPET) could not only suggest and rank competing etiologies, but also highlight peripheral impairment.
Clinical, resting pulmonary function testing, and CPET data from patients with SSc referred for exercise limitation between October 2009 and November 2015 were retrospectively analyzed in this bi-center study. Patients were categorized as having ILD, PV, LVD, and/or PML based on CPET response patterns and the diagnoses were matched with results from the reference investigations. The latter consisted of transthoracic echocardiography, chest computed tomography scan, and right heart catheterization (RHC).
Twenty-seven patients presented with CPET profiles consistent with ILD (n = 16), PV (n = 15), LVD (n = 5), and PML (n = 19). None of the subjects had a normal CPET profile. There was a statistically significant negative correlation between resting DLCO, on the one hand, and dead space to tidal volume ratio and alveolar-arterial gradient [P(Ai-a)O] on the other (p < 0.005). CPET identified 90% of patients with a mean pulmonary arterial pressure at rest ≥ 21 mmHg measured by RHC (n = 10). Peak P(Ai-a)O, taken independently from other variables, was crucial in distinguishing subjects with ILD from those without ILD (p < 0.05).
CPET is useful for the characterization of multifactorial exercise limitation in patients with SSc and in identifying SSc-related complications such as ILD and PV. This study also identifies PML as an underestimated cause of exercise limitation.
系统性硬化症(SSc)患者的运动受限通常是多因素的,与间质性肺病(ILD)、肺血管病变(PV)、左心室功能障碍(LVD)和/或周围/肌肉限制(PML)等并发症有关。我们假设心肺运动测试(CPET)不仅可以提示和排列竞争病因,还可以突出外周损伤。
本双中心研究回顾性分析了 2009 年 10 月至 2015 年 11 月因运动受限而接受 CPET 的 SSc 患者的临床、静息肺功能测试和 CPET 数据。根据 CPET 反应模式,将患者分为ILD、PV、LVD 和/或 PML ,CPET 诊断与参考调查结果相匹配。后者包括经胸超声心动图、胸部计算机断层扫描和右心导管检查(RHC)。
27 例患者的 CPET 表现与ILD(n=16)、PV(n=15)、LVD(n=5)和 PML(n=19)一致。所有患者的 CPET 均未见正常。静息 DLCO 与死腔/潮气量比和肺泡-动脉梯度[P(Ai-a)O]呈负相关(p<0.005)。CPET 识别出 90%静息平均肺动脉压≥21mmHg 的 RHC 测量值的患者(n=10)。峰值 P(Ai-a)O,独立于其他变量,对于区分ILD 患者和无ILD 患者至关重要(p<0.05)。
CPET 可用于 SSc 患者多因素运动受限的特征描述,并可识别ILD 和 PV 等 SSc 相关并发症。本研究还确定 PML 是运动受限的一个被低估的原因。